Foresight Diagnostics, Inc.

Foresight Diagnostics Inc. is a US-based company focused on advanced diagnostic solutions for cancer detection, utilizing cutting-edge technologies to enhance patient treatment outcomes. Founded in 2020 in Boulder, US, Foresight Diagnostics Inc. specializes in diagnostic solutions for oncology.

The company has successfully completed 4 deals to date, with its most recent funding round occurring on July 30, 2024, during which it raised USD 15. 00 mn in Series B funding from notable investors including Agent Capital and Stanford University. The company is led by CEO Jake Chabon, who is among the founders alongside Ash Alizadeh, David Kurtz, Jake Chabon, and Maximilian Diehn. Foresight Diagnostics specializes in advanced diagnostic solutions focused on cancer detection, particularly through their flagship offering, Foresight CLARITY™.

This ultra-sensitive minimal residual disease (MRD) platform employs proprietary PhasED-Seq™ technology to identify and monitor circulating tumor DNA (ctDNA) across various cancer types, delivering actionable insights at critical stages of patient treatment. The company's testing services cater to both biopharma and academic researchers, facilitating the development and execution of clinical trials and exploratory research in oncology. Foresight's customer base includes over 25 academic and biopharma partners, spanning diverse geographical markets such as North America, Europe, and Asia, where it addresses the clinical needs for precise disease monitoring and therapeutic response evaluation. Foresight Diagnostics generates revenue through partnerships and collaborations with biopharma companies and academic institutions, focusing on services related to their Foresight CLARITY™ platform.

Transactions typically involve business-to-business arrangements, where clients engage Foresight for custom testing, regulatory support, and access to their advanced diagnostic technologies. The company provides both lab-developed tests and personalized assays, with details on specific pricing structures tailored to each partnership. Foresight's revenue stream is reinforced by its regulatory expertise, facilitating the development of companion diagnostics and integrating MRD testing as endpoints in clinical trials, ensuring that clients benefit from both the technical capabilities and regulatory support in their research endeavors. In December 2025, Natera, Inc.

a portfolio company of Lightspeed Venture Partners, OrbiMed Advisors, Sofinnova Investments, Founders Fund, Claremont Creek Ventures, Alafi Capital, HealthCor Group, Harmony Partners, Franklin Templeton, RA Capital Management, and Transformation Capital acquired Foresight Diagnostics Inc. from Pear VC, Civilization Ventures, CU Healthcare Innovation Fund, Stanford University, BlueBird Ventures, Foresight Capital, Sadik Ventures, and Agent Capital for an upfront payment of USD 275 million and will receive additional payment of USD 175 million in all stock transaction upon achieving milestones.